| Name | Title | Contact Details |
|---|
GE Software is leading efforts to harness the power of the Industrial Internet, building off our powerful mix of industrial machine expertise, historical perspective, and software innovation. The Industrial Internet is changing the way we manage and maximize global economic output. For the first time in human history, critically important machines across the globe are communicating in real time. Combining these brilliant machines with best-in-class analytics delivers valuable new customer insights that were never before possible. GE`s investment in the Industrial Internet is spearheaded by the GE Software Center. This global innovation hub centered in San Ramon, California, is backed by 10,000 software professionals from across GE`s businesses around the world. Together, we are creating GE`s Predictivity™ solutions designed to save customers time, energy, and money.
Built around the visionary HL7 FHIR standard and powered by HAPI, Smile CDR is the most proven FHIR implementation in the world.
Banjo Health is a complementary partner in the healthcare technology marketplace by enhancing existing practices through Artificial Intelligence (AI) including Prior Authorization (PA).
Kaiko provides real-time and historical cryptocurrency trade data, order books, and aggregated prices through a cryptocurrency API, downloadable CSV files, and a livestream WebSocket. We cover 100+ crypto exchanges and 35,000+ trading pairs for Bitcoin...
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.